Education
About Us
Working with TipRanks
Follow Us
Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX
Earnings Data
Report Date
Aug 05, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.69Last Year’s EPS
0.89Same Quarter Last Year
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 2.77%
|Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with significant strategic wins, including the EXPAREL patent settlement and strong sales growth. However, some challenges remain, particularly in the transition of sales teams and adoption of new reimbursement pathways.Company Guidance
During the First Quarter 2025 Pacira BioSciences Earnings Conference Call, the company provided substantial guidance reflecting strong growth and strategic initiatives. Pacira introduced its "5x30" path to value creation, aimed at accelerating growth in its commercial business and advancing its innovative pipeline. Key achievements included settling patent litigation for EXPAREL, extending exclusivity to 2039, and reporting a 7% increase in average daily EXPAREL sales and volumes from 2024. The company's non-GAAP gross margin improved to 81%, benefiting from enhanced manufacturing efficiencies. Additionally, Pacira announced a $300 million stock repurchase program, signaling confidence in its growth outlook. The call also highlighted ongoing clinical progress, such as the Phase 2 ASCEND study of PCRX-201 for osteoarthritis, and the strategic acquisition of GQ Bio, enhancing its innovative gene therapy platform. The company's full-year 2025 revenue guidance was reaffirmed at $725 million to $765 million.EXPAREL Patent Settlement
Successfully settled patent infringement litigation for EXPAREL, extending exclusivity to 2039 and eliminating RDF royalty obligation, benefiting EXPAREL gross margins by a low single-digit percentage.
Growth in EXPAREL Sales
First quarter average daily EXPAREL sales and volumes were up approximately 7% over 2024, after adjusting for two fewer selling days in 2025.
PCRX-201 Progress
Patient dosing underway in Phase 2 ASCEND study of PCRX-201 in osteoarthritis of the knee, with promising early data suggesting potential for long-term pain relief.
Stock Repurchase Program
Announced a $300 million stock repurchase program, doubling the previous authorization, indicating confidence in growth outlook.
Strong Financial Performance
Consolidated first quarter non-GAAP gross margin improved to 81% from 72% last year, driven by improved costs and efficiencies.
---
PCRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PCRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $24.91 | $25.12 | +0.84% |
Feb 27, 2025 | $25.38 | $24.05 | -5.24% |
Nov 06, 2024 | $17.67 | $17.70 | +0.17% |
Jul 30, 2024 | $19.54 | $20.65 | +5.68% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Pacira Pharmaceuticals (PCRX) report earnings?
Pacira Pharmaceuticals (PCRX) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
What is Pacira Pharmaceuticals (PCRX) earnings time?
Pacira Pharmaceuticals (PCRX) earnings time is at Aug 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PCRX EPS forecast?
PCRX EPS forecast for the fiscal quarter 2025 (Q2) is 0.69.
---